Praxis Precision Medicines, Inc.
NASDAQ:PRAXBiotechnology
+$12.13 today
- Market cap
- $8.53B
- Beta
- 2.75
- P/E (TTM)
- -25.0
- EPS (TTM)
- -$11.31
Volume 0.43M
Average 0.45M
PRAX Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Praxis Precision Medicines, Inc.NASDAQ: PRAX
Research & Development · Q3 FY2026 · quarter ended Sep 2026
Research & development dips below year-ago levels
Q3 FY2026 research & development of $64.21M fell 2.4% year over year, behind the +17.6% change in trailing-twelve-month research & development. Sequentially, it fell 7.5% from the prior quarter. Over 3 fiscal years it compounded at +19.9% a year.
Context
- Research & development increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -2.4% toward the trailing-twelve-month pace of +17.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 267.12M USD
- Year-over-year change
- +75.3%
- 4-year CAGR
- +22.1%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 267.12M | +75.3% |
| FY2024 | 2024-12-31 | 152.41M | +75.7% |
| FY2023 | 2023-12-31 | 86.77M | -44.0% |
| FY2022 | 2022-12-31 | 155.04M | +28.9% |
| FY2021 | 2021-12-31 | 120.26M | — |
Research & Development vs competitors
How PRAX compares with its peers on the latest reported figures
- PRAX's LTM Sep 2026 research & development of $289.11M is the 5th highest of the 10 companies compared; the peer median is $187.86M.
- Its year-over-year change of +17.6% is the 5th highest of 10, against a peer median of -3.5%.
- Over three fiscal years its annual growth of +19.9% compares with a peer median of +18.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $1.23B | +30.7% | +29.9% | 33.3% | |
| LTM Jun 2026 | $400.72M | -3.9% | +5.3% | 11118.8% | |
| LTM Sep 2026 | $371.08M | +36.1% | +41.7% | — | |
| LTM Sep 2026 | $319.46M | -7.3% | -3.1% | 26.6% | |
| LTM Sep 2026 | $289.11M | +17.6% | +19.9% | — | |
| LTM Jun 2026 | $187.86M | -3.5% | +46.8% | 24.2% | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $162.51M | -21.6% | +18.9% | — |
| LTM Jun 2026 | $126.09M | +18.1% | +12.5% | 15.2% | |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $107.93M | +58.7% | +118.3% | 539.7% |
| LTM Dec 2025 | $31.8M | -27.0% | -0.3% | — | |
| Peer median (excluding PRAX) | $187.86M | -3.5% | +18.9% | 29.9% | |
Competitors are the stored peer set for PRAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 2.45M | 8.55M | 0 |
| Cost of Revenue | 0 | 154.44M | 86.77M | 152.41M | 140K |
| Gross Profit | 0 | (154.44M) | (84.32M) | (143.86M) | (140K) |
| Gross Margin | — | — | -3445.8% | -1682.0% | — |
| Research & Development | 120.26M | 155.04M | 86.77M | 152.41M | 267.12M |
| Selling, General & Admin | 47.08M | 59.55M | 42.05M | 56.31M | 59.08M |
| Operating Expenses | 167.33M | 60.55M | 42.05M | 56.31M | 326.06M |
| Depreciation & Amortization | 182K | 419K | 432K | 358K | 140K |
| EBITDA | (166.88M) | (213.57M) | (122.85M) | (182.46M) | (303.13M) |
| EBITDA Margin | — | — | -5020.2% | -2133.3% | — |
| Operating Income | (167.33M) | (214.99M) | (126.37M) | (200.17M) | (326.2M) |
| Operating Margin | — | — | -5164.4% | -2340.3% | — |
| Interest Income | 0 | 0 | 0 | 17.35M | 22.93M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 271K | 957K | 3.1M | 17.35M | 22.93M |
| Income Before Tax | (167.06M) | (214.03M) | (123.28M) | (182.82M) | (303.27M) |
| Pre-Tax Margin | — | — | -5037.9% | -2137.5% | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (167.06M) | (214.03M) | (123.28M) | (182.82M) | (303.27M) |
| Net Margin | — | — | -5037.9% | -2137.5% | — |
| EPS (Basic) | (58.96) | (69.33) | (18.69) | (10.21) | (13.48) |
| EPS (Diluted) | (58.96) | (69.33) | (18.69) | (10.21) | (13.48) |
| Weighted Avg Shares | 2.83M | 3.07M | 6.59M | 17.91M | 22.5M |
| Weighted Avg Shares (Diluted) | 2.83M | 3.07M | 6.59M | 17.91M | 22.5M |
Praxis Precision Medicines, Inc.
NASDAQ:PRAX
Intrinsic Alpha fair value
Locked
Current Price
$305.19
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.